ACTP

ACTP (Advanced Cell Therapy Portfolio) is a biotechnology company focused on developing next-generation cell therapies for oncology and autoimmune diseases. The company leverages a proprietary induced pluripotent stem cell (iPSC) platform to create off-the-shelf, standardized cell products, including CAR-T and CAR-NK cells. By utilizing iPSC technology, ACTP aims to overcome the limitations of traditional autologous therapies, such as high manufacturing costs and limited scalability. Their pipeline includes several candidates targeting hematological malignancies and solid tumors, with a focus on improving patient access and therapeutic efficacy.